Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Malignant Solid Neoplasm Clear all
Terminated Phase 1 Interventional Results available

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02097225
View directory record Official record
Conditions
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study, Trametinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

NCT06332755
View directory record Official record
Conditions
Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma, Malignant Melanoma
Interventions
Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting No phase listed Observational

Investigating the Impact of Proactive Palliative Care

NCT03667378
View directory record Official record
Conditions
Metastatic Solid Tumor Cancers, Locally Advanced Solid Tumor Cancers
Interventions
Expectations Survey (CanCORS), Values Survey (Serious Illness Care Program), Functional Assessment of Cancer Therapy-General (FACT-G), NCCN Distress Thermometer, Hospital Anxiety and Depression Scale (HADS), Quality of Communication (QOC), visits with a supportive care clinician
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors

NCT00365768
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions
Glutamine, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

NCT03237390
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

NCT06983743
View directory record Official record
Conditions
Metastatic Solid Tumors
Interventions
ERAS-0015, ERAS-0015 in combination
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Sarasota, Florida • Tampa, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

NCT06108050
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP898, Pembrolizumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 3 Interventional

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

NCT06915727
View directory record Official record
Conditions
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed No phase listed Observational

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

NCT00898079
View directory record Official record
Conditions
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
2,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
175
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

NCT01611857
View directory record Official record
Conditions
Malignant Solid Tumour, Gastroesophageal Cancer
Interventions
Tivantinib, FOLFOX
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Jul 23, 2026, 8:53 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

NCT05268666
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JBI-802
Drug
Lead sponsor
Jubilant Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of OTS167 in Patients With Solid Tumors

NCT01910545
View directory record Official record
Conditions
Solid Tumors, Metastatic Tumors
Interventions
OTS167IV
Drug
Lead sponsor
OncoTherapy Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma, Unresectable Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable NUT Carcinoma
Interventions
Abemaciclib, BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

NCT04866134
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
ERAS-007, ERAS-601
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

NCT04330664
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
MRTX849, TNO155
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 23, 2026, 8:53 AM EDT
Suspended Phase 2 Interventional

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

NCT05554380
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 23, 2026, 8:53 AM EDT
Terminated Phase 1 Interventional

Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04958434
View directory record Official record
Conditions
Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
Interventions
TST005
Drug
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 23, 2026, 8:53 AM EDT
Completed Phase 1 Interventional

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

NCT00004016
View directory record Official record
Conditions
Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon gamma
Biological
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 23, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

NCT05371132
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Lymphoma
Interventions
Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab, Intensity Modulated Radiation Therapy
Procedure · Radiation · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1 Interventional

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

NCT05277051
View directory record Official record
Conditions
Neoplasms
Interventions
Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Terminated Phase 1 Interventional

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

NCT06573294
View directory record Official record
Conditions
Advanced Malignant Solid Tumors, Metastatic Malignant Solid Tumors
Interventions
GEN1057, Premedication
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 8:53 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

NCT04266912
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Avelumab, Berzosertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 8:53 AM EDT